

Anti-viral photodynamic therapy in COVID-19 management: a novel approach in treating patients in early infection stages

Submission date 27/04/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/04/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 29/04/2021	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.

After a temporary slowdown in summer 2020 infection numbers and death rates have been increasing again in recent months leading to various restrictions of social and economic life in many countries. The latest developments of new vaccinations seem to be promising; however, large-scale production and worldwide distribution logistics take time while questions such as longevity of immune protection, long-term side-effects etc are remaining unclear at this point. Furthermore, vaccination is a preventive approach and not a treatment for acutely infected patients. Treatments are still needed to help people with COVID-19 infection. The aim of this study is to find out whether photodynamic therapy (PDT) with riboflavin and a specially designed light treatment kit would be able to fill this gap by helping people in the early stages of infection. This may lead to relief for hospitals and intensive care stations.

Who can participate?

Acutely infected COVID-19 patients aged 10-90 from Gandhi hospital in Tehran

What does the study involve?

Participants are randomly allocated to receive either photodynamic therapy plus daily testing for 5 days or to receive conventional care plus testing. Viral load is measured at the start of the study and after 24, 48, 72, 96, 120 and 168 hours.

What are the possible benefits and risks of participating?

Possible benefits are lowering the viral load and improving the symptoms of Covid-19 patients. There are no significant risks or side effects to be expected according to safety measurements that have been done before.

Where is the study run from?
Gandhi Hospital (Iran)

When is the study starting and how long is it expected to run for?
September 2020 to February 2021

Who is funding the study?
Weber Medical (Germany)

Who is the main contact?
Dr. med. Michael Weber
robert.weber@webermedical.com

Contact information

Type(s)
Scientific

Contact name
Dr Michael Weber

Contact details
Sohnreystasse 4
Lauenfoerde
Germany
37697
+49 (0)5273367780
robert.weber@webermedical.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Covid2021001

Study information

Scientific Title
Successful reduction of SARS-CoV-2 viral load by photodynamic therapy verified by quantitative PCR – a novel approach in treating patients in early infection stages

Study objectives

The objective of this study is to evaluate if Photodynamic Therapy (PDT) with riboflavin and a specially designed light treatment kit would be able to help people in the early stages of infection by reducing viral load and clinical symptoms.

Ethics approval required

Old ethics approval format

Ethics approval(s)

No ethical approval required because of the emergency COVID-19 situation in Tehran/Iran in November 2020

Study design

Interventional non-randomized study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

COVID-19 (SARS-CoV-2 infection)

Interventions

Patients are assigned in the sequence of hospital admission to two groups with 70 patients in the experiment (verum) group receiving daily Photodynamic Therapy and daily testing for 5 days and a control group receiving conventional care plus testing for 5 days. All patients in both groups had positive COVID-19 test results at the beginning of the study. They were in an early infection stage with mild symptoms like fever, dry cough, headache, hard breathing, fatigue etc. Quantitative PCR (QPCR) tests with Ct-viral load are performed on day 1, 2, 3, 4, 5 and 7 in the experiment group and on day 1, 3, 5 and 7 in the control group.

Intervention Type

Mixed

Primary outcome measure

Viral load measured using the QPCR test (Ct value) at baseline, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 168 hours

Secondary outcome measures

Clinical symptoms measured using the visual analogue score (VAS) at baseline, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 168 hours

Overall study start date

02/09/2020

Completion date

28/02/2021

Eligibility

Key inclusion criteria

1. Men and women
2. Aged 10-90 years
3. Early stages of COVID-19 (SARS-CoV-2 infection)

Participant type(s)

Patient

Age group

Mixed

Sex

Both

Target number of participants

140

Total final enrolment

140

Key exclusion criteria

1. Late infection stages
2. Pregnant women
3. Children aged under 10 years

Date of first enrolment

01/11/2020

Date of final enrolment

15/02/2021

Locations

Countries of recruitment

Iran

Study participating centre

Gandhi Hospital

Gandhi St, No. 130

Tehran
Iran
1000

Sponsor information

Organisation

International Society for Medical Laser Applications

Sponsor details

Loensstr. 10
Lauenfoerde
Germany
37697
+49 (0)52733677818
info@isla-laser.org

Sponsor type

Research organisation

Website

isla-laser.org

Funder(s)

Funder type

Industry

Funder Name

Weber Medical

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

01/05/2021

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

IPD sharing plan summary

Other